Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Jurinovic, Vindi [VerfasserIn]   i
 Metzner, Bernd [VerfasserIn]   i
 Pfreundschuh, Michael [VerfasserIn]   i
 Schmitz, Norbert [VerfasserIn]   i
 Wandt, Hannes [VerfasserIn]   i
 Keller, Ulrich [VerfasserIn]   i
 Dreger, Peter [VerfasserIn]   i
 Dreyling, Martin [VerfasserIn]   i
 Hiddemann, Wolfgang [VerfasserIn]   i
 Unterhalt, Michael [VerfasserIn]   i
 Hoster, Eva [VerfasserIn]   i
 Weigert, Oliver [VerfasserIn]   i
Titel:Autologous stem cell transplantation for patients with early progression of follicular lymphoma
Titelzusatz:a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group
Verf.angabe:Vindi Jurinovic, Bernd Metzner, Michael Pfreundschuh, Norbert Schmitz, Hannes Wandt, Ulrich Keller, Peter Dreger, Martin Dreyling, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Oliver Weigert
E-Jahr:2018
Jahr: 29 March 2018
Umfang:8 S.
Fussnoten:Gesehen am 05.11.2019
Titel Quelle:Enthalten in: Biology of blood and marrow transplantation
Ort Quelle:[S.l.] : Elsevier Health Sciences, 1998
Jahr Quelle:2018
Band/Heft Quelle:24(2018), 6, Seite 1172-1179
ISSN Quelle:1523-6536
Abstract:Patients with follicular lymphoma (FL) and progression of disease (POD) within 24 months after frontline treatment (POD24) have poor overall survival (OS). The optimal salvage treatment for these patients is unknown. We assessed the role of high-dose therapy and autologous stem cell transplantation (ASCT) in transplant-eligible patients. We analyzed 162 patients with advanced-stage FL who had received frontline treatment within the GLSG1996 or GLSG2000 trials. All patients had POD at age ≤ 65 years and had not received a prior transplant. Second-line treatment was not specified by study protocols. Survival was calculated from time of second-line treatment. Eighteen patients (11%) progressed (n = 16) or died (n = 2) during cytoreductive second-line treatment (considered “cytoreduction failure”); none received ASCT, and their median second-line OS was <1 year. A total of 113 patients had POD24 (70%), whereas 49 had POD after 24 months (30%). Sixty-three patients without cytoreduction failure received ASCT (39%), and 81 received no transplant (50%). In patients with POD24, a significant survival benefit was associated with ASCT with a 5-year second-line progression-free survival for ASCT versus no transplant of 51% versus 19% (hazard ratio, .38; 95% confidence interval, .24 to .62; P < .0001) and a 5-year second-line OS of 77% versus 59% (hazard ratio, .54, 95% confidence interval, .30 to .95; P = .031). Thus, ASCT is an effective treatment option for transplant-eligible patients with high-risk FL as identified by POD24 and should be evaluated in prospective clinical trials.
DOI:doi:10.1016/j.bbmt.2018.03.022
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1016/j.bbmt.2018.03.022
 Volltext: http://www.sciencedirect.com/science/article/pii/S1083879118301563
 DOI: https://doi.org/10.1016/j.bbmt.2018.03.022
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Autologous stem cell transplantation
 Early progression of disease
 Follicular lymphoma
 Salvage treatment
 Transplant eligibility
K10plus-PPN:1681090074
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68450453   QR-Code
zum Seitenanfang